Abstract: Radio-frequency identification (RFID) tag readers or sensors interrogate and locate RFID tags in stores, warehouses, and other environments. Unfortunately, these sensors are vulnerable to intrusions, including attacks that can expose any computer network to which the sensors are coupled. Attacks like these can be prevented using a secure booting process for distributing and loading an operating system and/or other software onto each sensor. When the sensor first boots up, it validates a pair of locally stored binary files, e.g., using a pair of locally stored digital keys. Once booted, it establishes a secure connection to a controller, then downloads, validates, and executes a binary file from the controller. Executing the binary file from the controller loads an operating system kernel into the sensor's memory for secure operation.

Abstract: A stand-alone web-based rapid anatomical documentation (RAD) system searches for ICD codes linked to key words that are applied to a standards-based structured vocabulary. The RAD system provides a search screen divided into a plurality of display regions for selecting a search type from the search screen. The search type includes a text search and anatomy search. Based on the type of search initialed, search filters and ICD codes are made available. Selecting at least one search filter causes an update of the search filters and ICD codes available, wherein the selection of the search filters can be repeated until a number of codes available reach a minimum value. Each ICD code is linked to keywords hierarchically organized and associated with the search filters, links to defined regions on anatomical art images and clinically relevant information.

Abstract: The present invention provides compositions and methods for assessing profiles of catalytically active enzymes in compositions containing a plurality of proteins. In preferred embodiments, the enzyme is a hydrolase, most preferably a cysteine protease. The methods described herein use activity based probes (“ABPs”) that have an affinity moiety for directing the binding of the ABP to one or more catalytically active target enzymes, a reactive group for forming a covalent bond at an active site of the target enzyme(s), and a TAG (e.g., a detectable label, preferably a fluorophore). One or more ABPs may be combined with a protein-containing sample under conditions for binding and reaction of the ABP(s) with target enzyme(s) that are present in the sample. The resulting products may then be used to assess the active enzyme profile of the sample, and can be correlated to the presence, amount, or activity of one or more target enzyme(s) present in the original complex protein mixture.

Abstract: The present invention is directed to a method of treatment of a malcondition that can be regulated or normalized via inhibition of DPP-IV. The method involves administration of an effective amount of a pyrrolidine compound of the invention, such as would be present in a pharmaceutical composition of the invention, to mammals, especially humans, to affect a malcondition that can be regulated or normalized via inhibition of DPP-IV.

Abstract: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CRiRii, R1, R2, R3, R4 and R5 are as described herein.

Abstract: The present invention provides compositions and methods for assessing profiles of catalytically active enzymes in compositions containing a plurality of proteins. In preferred embodiments, the enzyme is a hydrolase, most preferably a cysteine protease. The methods described herein use activity based probes (“ABPs”) that have an affinity moiety for directing the binding of the ABP to one or more catalytically active target enzymes, a reactive group for forming a covalent bond at an active site of the target enzyme(s), and a TAG (e.g., a detectable label, preferably a fluorophore). One or more ABPs may be combined with a protein-containing sample under conditions for binding and reaction of the ABP(s) with target enzyme(s) that are present in the sample. The resulting products may then be used to assess the active enzyme profile of the sample, and can be correlated to the presence, amount, or activity of one or more target enzyme(s) present in the original complex protein mixture.

Abstract: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.

Abstract: Compounds that selectively inhibit dipeptidyl peptidase-IV over closely related dipeptidyl peptidases are those of Formula (I): as well as pharmaceutically acceptable salts thereof, cyclic isomers thereof, prodrugs thereof, and solvates thereof, where all the variables are defined herein. These compounds can be used, alone or in combination with other drugs, for the treatment of diabetes and related diseases.

Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.

Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.

Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV (DPP-IV) inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.

Abstract: Certain constrained cyano compounds are useful as inhibitors of post-proline/alanine cleaving amino-dipeptidases. Accordingly, these compounds can be employed, alone or with another therapeutic agent, to treat diabetes (especially, Type II diabetes), hyperglycemia, Syndrome X, diabetic complications, hyperinsulinemia, obesity, atherosclerosis and related diseases, as well as various immunomodulatory diseases and chronic inflammatory bowel disease.

Abstract: Disclosed is a method and system for providing constant critical AC electrical load with primary, secondary, and in some cases a tertiary source of power with higher reliability and lower operating and capital costs and lower emissions than the traditional utility supply, uninterruptible power supply (UPS), and battery primary power source, and diesel generator back-up systems that are predominately used today. Specifically, the disclosed system utilizes on-site power generation to provide primary power and includes full utility and UPS/DC storage back-up systems.

Abstract: A spray hood device for containing a fluid spray leak in a fluid-based cooling system. A cover member surrounds a given component subject to a fluid spray leak, containing fluid sprays, preventing the fluid sprays from reaching equipment therebelow and minimizing fluid leakage damage.

Abstract: A cooling system employing redundant system components is disclosed. The system includes multiple sets of heat: exchanger units, with each set being in fluid communication with a separate, independently operated fluid pump unit. The heat exchanger units are arranged in at least one row of heat exchanger units. The two sets of heat exchanger units are evenly interspersed with each other along the row of heat exchanger units so that a substantially uniform distribution of cooled air is provided in the event one fluid pump unit fails.

Abstract: A cooling system and method employing separation chutes and baffles is disclosed. The separation chutes separate the cooled air descending from a heat exchanger positioned above heat-generating equipment in an equipment room from heated air ascending from the heat-generating equipment. Separation of the airflows reduces turbulence and increases cooling efficiencies. The separation chutes are made of a variety of materials, both rigid and flexible, for a variety of applications.

Abstract: A system, method and apparatus for detecting a fluid leak in a fluid based cooling system and purging the fluid therein under various conditions. The system, method and apparatus detect fluid levels in the cooling system, fluid pressure in the cooling system and fluid spraying and dripping from the cooling system. Upon an affirmative determination of low fluid levels, low fluid pressure or fluid spraying and dripping from one or more locations in the cooling system, the device automatically purges the fluid from the cooling system. Accordingly, in an overhead fluid-based cooling system, any damage to objects below from having fluid leaked thereon is minimized.